XERS News and Press, Xeris Pharmaceuticals Inc.

2024-07-08 07:31:04 ET More on Xeris Pharmaceuticals Xeris Biopharma Holdings, Inc. (XERS) Q1 2024 Earnings Call Transcript Xeris stock jumps 14% on Phase 2 data for injected levothyroxine Read the full article on Seeking Alpha For further details see: Xe...

John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track reco...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2024, the Compensation Committee of Xeris’ Boar...

2024-06-11 12:08:45 ET Summary Corcept Therapeutics Incorporated share prices were initially suppressed after a court ruling that Teva's generic version of Korlym would not infringe on its patents. However, the company is preparing an NDA for Korlym's successor, which could be app...

In patients with Cushing’s syndrome maintained on Recorlev, a lower baseline mUFC was associated with higher cortisol normalization rate. Lower mUFC at baseline was also associated with lower maintenance dose requirements and lower rates of potentially clinically important liver-re...

2024-05-30 10:29:56 ET More on Xeris Pharmaceuticals Xeris Biopharma Holdings, Inc. (XERS) Q1 2024 Earnings Call Transcript Xeris Biopharma: Checking-In On One Of My 'Top Ideas' Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript Xeris Pharmaceuticals Q1 ...

XeriSol™ formulation enabled predictable bioavailability and sustained levels of levothyroxine in a once-weekly subcutaneous presentation Once-weekly SC levothyroxine (XP-8121) participants normalized TSH/T4 levels using 45% less drug than would be needed for their daily oral dose ...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a f...

2024-05-10 10:00:12 ET David Amsellem from Piper Sandler issued a price target of $3.00 for XERS on 2024-05-10 08:29:00. The adjusted price target was set to $3.00. At the time of the announcement, XERS was trading at $1.8469. The overall price target consensus is at $6....

2024-05-09 12:49:14 ET Xeris Biopharma Holdings, Inc. (XERS) Q1 2024 Earnings Conference Call May 09, 2024, 08:30 ET Company Participants Allison Wey - SVP, IR & Corporate Communications Paul Edick - Chairman & CEO Steven Pieper - CFO Conference Cal...